Pseudohypoparathyroidism
10
2
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old
Theophylline Treatment for Pseudohypoparathyroidism
Theophylline for Treatment of Pseudohypoparathyroidism
Natural History Study of Parathyroid Disorders
IDMet (RaDiCo Cohort) (RaDiCo-IDMet)
Studies of States With Resistance to Vitamin D and Parathyroid Hormone
Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
Characterization of Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism
Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)
Study of the Regulation of Parathyroid Hormone Secretion in Pseudohypoparathyroidism